NASDAQ
BLPH

Bellerophon Therapeutics Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Bellerophon Therapeutics Inc Stock Price

Vitals

Today's Low:
$0.4038
Today's High:
$0.4449
Open Price:
$0.415
52W Low:
$0.674
52W High:
$12.58
Prev. Close:
$0.438
Volume:
53611

Company Statistics

Market Cap.:
$10.18 million
Book Value:
1.015
Revenue TTM:
$5.64 million
Operating Margin TTM:
-270.71%
Gross Profit TTM:
$0
Profit Margin:
-201.56%
Return on Assets TTM:
-50.61%
Return on Equity TTM:
-84.92%

Company Profile

Bellerophon Therapeutics Inc had its IPO on 2015-02-13 under the ticker symbol BLPH.

The company operates in the Healthcare sector and Biotechnology industry. Bellerophon Therapeutics Inc has a staff strength of 18 employees.

Stock update

Shares of Bellerophon Therapeutics Inc opened at $0.42 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.4 - $0.44, and closed at $0.44.

This is a +1.55% increase from the previous day's closing price.

A total volume of 53,611 shares were traded at the close of the day’s session.

In the last one week, shares of Bellerophon Therapeutics Inc have increased by +2.02%.

Bellerophon Therapeutics Inc's Key Ratios

Bellerophon Therapeutics Inc has a market cap of $10.18 million, indicating a price to book ratio of 1.0544 and a price to sales ratio of 0.

In the last 12-months Bellerophon Therapeutics Inc’s revenue was $5.64 million with a gross profit of $0 and an EBITDA of $-15223000. The EBITDA ratio measures Bellerophon Therapeutics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Bellerophon Therapeutics Inc’s operating margin was -270.71% while its return on assets stood at -50.61% with a return of equity of -84.92%.

In Q1, Bellerophon Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Bellerophon Therapeutics Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG
0

Its diluted EPS in the last 12-months stands at $-0.17 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Bellerophon Therapeutics Inc’s profitability.

Bellerophon Therapeutics Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0.1437. Its price to sales ratio in the trailing 12-months stood at 0.

Bellerophon Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$15.97 million
Total Liabilities
$5.36 million
Operating Cash Flow
$0
Capital Expenditure
$0
Dividend Payout Ratio
0%

Bellerophon Therapeutics Inc ended 2024 with $15.97 million in total assets and $0 in total liabilities. Its intangible assets were valued at $15.97 million while shareholder equity stood at $10.60 million.

Bellerophon Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $5.36 million in other current liabilities, 104000.00 in common stock, $-249256000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $15.17 million and cash and short-term investments were $15.17 million. The company’s total short-term debt was $8,000 while long-term debt stood at $0.

Bellerophon Therapeutics Inc’s total current assets stands at $15.77 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $1.07 million and inventory worth $0.

In 2024, Bellerophon Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Bellerophon Therapeutics Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$0.44
52-Week High
$12.58
52-Week Low
$0.674
Analyst Target Price
$25.75

Bellerophon Therapeutics Inc stock is currently trading at $0.44 per share. It touched a 52-week high of $12.58 and a 52-week low of $12.58. Analysts tracking the stock have a 12-month average target price of $25.75.

Its 50-day moving average was $0.51 and 200-day moving average was $3.32 The short ratio stood at 2.17 indicating a short percent outstanding of 0%.

Around 411.2% of the company’s stock are held by insiders while 4442.9% are held by institutions.

Frequently Asked Questions About Bellerophon Therapeutics Inc

The stock symbol (also called stock or share ticker) of Bellerophon Therapeutics Inc is BLPH

The IPO of Bellerophon Therapeutics Inc took place on 2015-02-13

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$520.25
2.6
+0.5%
$4.01
-0.05
-1.23%
AltaGas Ltd (ATGFF)
$19.75
0.11
+0.56%
$2.89
-0.04
-1.37%
$454.7
-26.05
-5.42%
$33.13
-1.15
-3.34%
$527.7
-13.05
-2.41%
$0.01
0
+1.4%
$3.04
-0.06
-1.94%
$32.86
0.32
+0.98%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse, which is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.

Address

184 Liberty Corner Road, Warren, NJ, United States, 07059